gwinn

AKESOgen, Expands Footprint in Gwinnett County, Metro Atlanta


Life Science Startup, AKESOgen, Expands Footprint in Gwinnett County, Metro Atlanta
Company triples space, plans for future growth
 

(GWINNETT- METRO ATLANTA) December 18, 2013 – Genomics and biorepository services company, AKESOgen, Inc., joined Gwinnett Chamber Economic Development and the Georgia Department of Economic Development to announce its expansion and new location in Gwinnett County, metro Atlanta, Georgia. AKESOgen will more than triple its square footage with of its move to a 13,727-square-foot facility, located at 3155 Northwoods Place in the City of Peachtree Corners. The company expects to add up to an additional ten employees in 2014.

“Since our inception just over three years ago, we have been impressed with the resources, support, and growth opportunities available to biotech companies in Gwinnett County, metro Atlanta and Georgia,” stated Dr. Mark Bouzyk, Chief Scientific Officer for AKESOgen, Inc. “This larger facility will both strengthen our ability to deliver genomics research and development, as well as complement our existing competence in the biotech field.”

Earlier this year, AKESOgen joined the Georgia Department of Economic Development, Innovation Crescent, and six additional life science companies to promote Georgia as a life science hub at the 2013 BIO International Convention, held in Chicago.

“Innovative life science companies such as AKESOgen are what make our state the healthcare hub of the Southeast,” said Carol Henderson, director of life sciences and technology at the Georgia Department of Economic Development. “AKESOgen will lay the foundation for tomorrow’s life science discovery, and we are confident that Georgia’s pro-business climate can support the company in doing so.”

Gwinnett County and AKESOgen are located in the heart of Georgia’s Innovation Crescent, a geographical region and collaborative partnership of more than 15 counties and economic development entities all dedicated to supporting the state’s life science and technology growth. Anchored by Atlanta’s Hartsfield-Jackson International Airport on one end and the University of Georgia in Athens-Clarke County on the other, the Innovation Crescent encompasses a wide range of companies and institutions committed to furthering life science research. AKESOgen represents one of these companies and will be surrounded by the resources of top research organizations in the Southeast.

“Our goal as a region is to broaden and enhance life science and technology in the region and an expansion such as this one demonstrates the success of those efforts,” commented Nick Masino, Chair of Georgia’s Innovation Crescent and Senior Vice President of Gwinnett Chamber Economic Development and Partnership Gwinnett. “As a member of the Innovation Crescent Regional Partnership, Gwinnett Chamber Economic Development actively works to promote, support and encourage the growth of companies in these industries.”

Gwinnett County Board of Commission Chairman Charlotte Nash, stated, “This expansion supports Gwinnett’s reputation as a hub for research, development and innovation in the Southeast. AKESOgen remains an important contributor to our life sciences community and we are grateful for its decision to remain and grow in Gwinnett.”

According to data released by the Bureau of Labor and Statistics, nearly 30 life science and biotechnology companies call Gwinnett home. AKESOgen represents the third Gwinnett company involved in one of these industries to expand in the past six months alone.

“We welcome AKESOgen, and view its investment in the City of Peachtree Corners and Gwinnett as a testament to our community’s strength in this developing, vibrant and progressive industry,” said City of Peachtree Corners Mayor Mike Mason.

AKESOgen provides biomarker profiling and genomics services for the research and development market, including biobanking, DNA/RNA extraction, and genetic technologies. Founded in 2010, the company serves the clinical, pharmaceutical, biotechnology, academic and government sectors.

To learn more about AKESOgen, please visit www.akesogen.com.

For more information, or to learn how to get involved in local economic development efforts, please visit www.gwinnetteconomicdevelopment.com.

About AKESOgen, Inc.
AKESOgen is an integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the R&D market in to CLIA standards. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and agricultural sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility.

About Gwinnett Chamber Economic Development
Gwinnett Chamber Economic Development globally markets Gwinnett as the premier location in metro Atlanta and the State of Georgia for growing and conducting business. By encouraging investment and trade into the county through relocation and expansion assistance, the organization works with local and regional partners to bring technology, health sciences and services, advanced manufacturing, supply chain management, and corporate headquarters to the community. Home to FORTUNE 500 and 1000 companies, Gwinnett County hosts a wide range of businesses from industry giants, to international companies and homegrown start-ups. Success lives here- www.gwinnetteconomicdevelopment.com.

Media Contact

Dr. Mark Bouzyk | mbouzyk@akesogen.com | 404.771.8667
Sasha Ugi | Sasha@gwinnettchamber.org | 678.584.2261

– See more at: http://www.akesogen.com/?page=pr-2013-12-18#sthash.qrWs5s9h.dpuf

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

Wnt signaling in triple negative breast cancer is associated with metastasis.

Wnt signaling in triple negative breast cancer is associated with metastasis.

Dey N, Barwick BG, Moreno CS, Ordanic-Kodani M, Chen Z, Oprea-Ilies G, Tang W, Catzavelos C, Kerstann KF, Sledge GW Jr, Abramovitz M, Bouzyk M, De P, Leyland-Jones BR.

BMC Cancer. 2013 Nov 10;13:537. doi: 10.1186/1471-2407-13-537.

PMID: 24209998 [PubMed – in process] Free Article

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner

Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.

Dey N, Young B, Abramovitz M, Bouzyk M, Barwick B, De P, Leyland-Jones B.

PLoS One. 2013 Oct 15;8(10):e77425. doi: 10.1371/journal.pone.0077425. eCollection 2013.

PMID: 24143235 [PubMed – indexed for MEDLINE]Free Article

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
id

AKESOgen and Identitas Partner

 

 

AKESOgen and Identitas partner to provide a comprehensive Next Generation Forensic profiling solution

 

New York, NY, USA and Norcross, GA, USA – August 16th 2013 – Identitas Corp., a leader in forensic phenotyping and AKESOgen, the genomics and biorepository services company today announced a global commercial partnership to offer the forensic industry an innovative turn-key phenotypic screening solution that allows investigators to generate more comprehensive leads from DNA samples than had previously been possible. Financial terms were not disclosed.

“Our unique technology creates highly specific phenotypic predictions from DNA, combining inferences on biogeographic ancestry, extended relatedness/kinship, gender, Y and mitochondrial haplotype, and physical appearance such as hair and eye color. ISAS™ is able to generate investigative leads rapidly using only a single aliquot of DNA. We evaluate genome-wide single nucleotide polymorphisms (SNPs), to extract greater insight from DNA samples than has previously been possible” said Dr. Aruna Bansal, CIO of Identitas.

“We are excited to be working with Identitas to provide a comprehensive solution which we believe is unique in the forensic market and will have tremendous utility for enhanced phenotyping of individuals for a variety of applications including missing person identification as well as investigative lead generation, to complement standard panels such as CODIS.” commented Dr. Mark Bouzyk, CSO of AKESOgen.

The partnership will harness the combined strengths of both companies: AKESOgen will provide an end-to-end genetic analysis package powered by Identitas’s proprietary ISAS™ software analysis tool. ISAS™ employs a computationally powerful approach that interrogates single nucleotide polymorphisms (SNPs) to develop a profile that describes the physical appearance of an individual. AKESOgen has entered in to a license agreement with Identitas for access to the ISAS™ software, enabling customers a seamless delivery of an enhanced phenotypic profile from receipt of DNA.

–ENDS–
Notes to Editors:

Contact details

Mark Bouzyk, PhD, Chief Scientific Officer, AKESOgen, Inc.
T: +1 855 661 8920 (Toll Free)
C: +1 404 771 8667
E: mbouzyk@akesogen.com

Aruna Bansal MSc, PhD, CStat, CSci, Chief Information Officer, Identitas Corp.
C: +44 1223 421 662
E: bansal@identitascorp.com

About AKESOgen, Inc.

AKESOgen is an integrated genomics and company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the R&D market in a CLIA environment. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the government, academic, pharmaceutical, biotechnology, clinical testing and agricultural sectors. AKESOgen provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit www.akesogen.com

About Identitas Corp.

Identitas Corp. is a forensic genomics company developing better ways to extract information from genetic evidence. Their lead software product, ISAS™, is an all-in-one solution that generates highly detailed profiles from a single DNA sample. ISAS™ provides simple, intuitive reports of high resolution data that describe familial relatedness, bio-geographic ancestry/location of origin, and visual phenotyping. For more information, visit www.identitascorp.com

– See more at: http://www.akesogen.com/?page=pr-2013-08-16#sthash.DZmANyjv.dpuf

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

AKESOgen completes 25,000 Nucleic Acid extractions in 18 months

AKESOgen completes 25,000 Nucleic Acid extractions in 18 months. “We are delighted to announce this important milestone in our DNA and RNA extraction services. During this time we have isolated, quantified and normalized DNA and RNA from sources as diverse as saliva, whole blood, buffy coat, buccal cells and paraffin embedded formalin fixed tissue for a multitude of projects. We anticipate this volume will increase in the coming months with several important projects in our pipeline.” commented Dr. Dawen Xie, Senior Director, Scientific Affairs. 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail